Our facilities
Aurillac
Microbiome Centre of excellence – Aurillac France
Welcome to our centre of excellence for Microbiome therapeutics and Next Generation Probiotics in Aurillac, France. As the world leading CDMO in our space and at the heart of the Massif Central Mountains, Aurillac is the centre both historically & technologically for Biose Industrie with the capacity to accept our clients laboratory strains, develop processes and manufacture at GMP level for both the Active bacterial Ingredient (Drug Substance) and the finished product (Drug Product) at Clinical and Commercial levels.
With our 52000m² site we have over 15000L of GMP fermentation suites with continuous concentration (centrifuge and TFF) and freeze drying for anaerobic & aerobic bacteria. Our state-of-the-art plant also includes Clinical and Commercial capacity for different finished product delivery mechanisms such as Encapsulation, Tabletting, Sachets and Oils and creams for topical application. In addition, we can design bespoke formulation solutions for different intestinal delivery of your product using our own enteric coating, banding and “Capsules in capsules” technology.
This facility is inspected by the French ANSM (and hence the EMA) as a GMP pharma site to manufacture Clinical and commercial batches of Live Biotherapeutic products, both Drug Substance and Drug Products, cosmetics and food supplements.
Visitors’ Map
Click on the departments to find out more.
Past and future investment
In 2020, Biose Industrie marked a significant milestone with the successful completion of its inaugural fundraising round, securing a notable €40 million. This financial boost propelled our expansion efforts, as evidenced by the addition of over 7000L of volume in a new cutting edge drug substance expansion spanning 2700m². We also demonstrated our commitment to innovation underscored by the integration of a state-of-the-art Clinical Drug Product module, encompassing essential processes such as blending, encapsulation, blistering, banding, enteric coating and the formulation of creams and oils.
Fast forward to 2023, and Biose Industrie stands poised for even greater achievements, thanks to the culmination of a second round of joint investment, amassing a substantial €80 million. This injection of capital has empowered us to enhance our range of services offered on a global scale. One of our major initiatives was the creation of a Tech Transfer Laboratoty in Boston, USA our initiatives is the establishment of a Tech Transfer laboratory in Boston, USA, serving as a strategic hub for supporting our esteemed US clients in process development and validation. This proactive approach ensures seamless tech transfer to our facilities in France, facilitates efficient scale-up and further strenghtens Biose Industrie’s position as a leader in the pharmaceutical industry.
In addition to our current endeavors, the years 2024-2025 will witness even bigger expansion of our facilities to accommodate the growing demands of our global customer base, reaffirming our commitment to excellence and innovation in pharmaceutical manufacturing.